Patritumab deruxtecan
Modify Date: 2024-01-03 18:00:58
Patritumab deruxtecan structure
|
Common Name | Patritumab deruxtecan | ||
|---|---|---|---|---|
| CAS Number | 2227102-46-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Patritumab deruxtecanPatritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1]. |
| Name | Patritumab deruxtecan |
|---|
| Description | Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Patritumab deruxtecan 对表达 HER3 突变的乳腺癌细胞表现出活性，无论HER2是否过表达[1]。 Patritumab deruxtecan (0-100 nM) 以浓度依赖性方式结合所有 HER3 突变体和 HER3WT MDA-MB-231 细胞的表面，但不结合 HER3< sup>EV 细胞[1]. |
| References |
| No Any Chemical & Physical Properties |